333 related articles for article (PubMed ID: 31479430)
21. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
22. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
[TBL] [Abstract][Full Text] [Related]
23. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
Lee JE; Bennett CF; Cooper TA
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4221-6. PubMed ID: 22371589
[TBL] [Abstract][Full Text] [Related]
24. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2.
Cardani R; Mancinelli E; Rotondo G; Sansone V; Meola G
Eur J Histochem; 2006; 50(3):177-82. PubMed ID: 16920640
[TBL] [Abstract][Full Text] [Related]
25. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
[TBL] [Abstract][Full Text] [Related]
26. Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.
Stoodley J; Vallejo-Bedia F; Seone-Miraz D; Debasa-Mouce M; Wood MJA; Varela MA
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36769018
[TBL] [Abstract][Full Text] [Related]
27. Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1.
Timchenko L
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877772
[TBL] [Abstract][Full Text] [Related]
28. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.
Wheeler TM; Sobczak K; Lueck JD; Osborne RJ; Lin X; Dirksen RT; Thornton CA
Science; 2009 Jul; 325(5938):336-9. PubMed ID: 19608921
[TBL] [Abstract][Full Text] [Related]
29. Calcitriol increases MBNL1 expression and alleviates myotonic dystrophy phenotypes in HSA
Huang K; Wang DD; Hu WB; Zeng WQ; Xu X; Li QX; Bi FF; Yang H; Qiu J
J Transl Med; 2022 Dec; 20(1):588. PubMed ID: 36510245
[TBL] [Abstract][Full Text] [Related]
30. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
31. Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.
Wang M; Weng WC; Stock L; Lindquist D; Martinez A; Gourdon G; Timchenko N; Snape M; Timchenko L
Mol Cell Biol; 2019 Nov; 39(21):. PubMed ID: 31383751
[TBL] [Abstract][Full Text] [Related]
32. Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in skeletal muscle of DM1 mice.
Ravel-Chapuis A; Bélanger G; Côté J; Michel RN; Jasmin BJ
Hum Mol Genet; 2017 Jun; 26(12):2192-2206. PubMed ID: 28369518
[TBL] [Abstract][Full Text] [Related]
33. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
34. Modeling muscle regeneration in RNA toxicity mice.
Yadava RS; Mandal M; Giese JM; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2021 Jun; 30(12):1111-1130. PubMed ID: 33864373
[TBL] [Abstract][Full Text] [Related]
35. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
[TBL] [Abstract][Full Text] [Related]
36. A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.
Gudde AE; González-Barriga A; van den Broek WJ; Wieringa B; Wansink DG
Hum Mol Genet; 2016 Apr; 25(8):1648-62. PubMed ID: 26908607
[TBL] [Abstract][Full Text] [Related]
37. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
38. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.
Chau A; Kalsotra A
Dev Dyn; 2015 Mar; 244(3):377-90. PubMed ID: 25504326
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.
Bisset DR; Stepniak-Konieczna EA; Zavaljevski M; Wei J; Carter GT; Weiss MD; Chamberlain JR
Hum Mol Genet; 2015 Sep; 24(17):4971-83. PubMed ID: 26082468
[TBL] [Abstract][Full Text] [Related]
40. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
